AB84547

Anti-CIP2A antibody

Name: Anti-CIP2A antibody (ab84547) | Abcam
Brand: Abcam Limited
SKU: AB84547
Price: 535 USD
Availability: InStock
Rating: 4 (1 reviews)

(1 Review)

(11 Publications)

Rabbit Polyclonal CIP2A antibody. Suitable for IHC-P and reacts with Human samples. Cited in 11 publications. Immunogen corresponding to Synthetic Peptide within Human CIP2A aa 550-600.

View Alternative Names

KIAA1524, CIP2A, Protein CIP2A, Cancerous inhibitor of PP2A, p90 autoantigen

3 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Detection of Human CIP2A by Immunohistochemistry.Sample : FFPE section of Human ovarian carcinoma.Antibody : ab84547 used at a dilution of 1/250.Detection : DAB staining.

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Detection of Human CIP2A by Immunohistochemistry.Sample : FFPE section of Human colon carcinoma.Antibody : ab84547 used at a dilution of 1/250.Detection : DAB staining.

IHC-P

PubMed

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Immunohistochemical analysis of Human breast tumour tissue, staining CIP2A with ab84547 at 1/100 dilution.

Image from Tseng LM et al., Breast Cancer Res. 2012 Apr 26;14(2):R68 Fig 6.; doi:10.1186/bcr3175; 26 April 2012, Breast Cancer Research 2012, 14:R68

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IHC-P

applications

Immunogen

Synthetic Peptide within Human CIP2A aa 550-600. The exact immunogen used to generate this antibody is proprietary information.

Q8TCG1

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol." } } }

style

left-column

Product details

Concentration is optimized for IHC and not determined.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 6.8 - 7.4 Preservative: 0.09% Sodium azide Constituents: Tris buffered saline, 0.1% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

+4°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Acts as an inhibitor of protein phosphatase PP2A (PubMed : 17632056). Promotes anchorage-independent cell growth and tumor formation by preventing dephosphorylation of MYC, thereby stabilizing MYC in human malignancies (PubMed : 17632056). Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei (PubMed : 35121901, PubMed : 35842428, PubMed : 37165191, PubMed : 37316668). Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane : following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss (PubMed : 37165191, PubMed : 37316668).

See full target information CIP2A

style

left-column

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 15:22382 PubMed40594400

2025

Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Alice Filipe,Sayeh Saravi,Denis Mustafov,Suzana Panfilov,Simran Banger,Seyedehnajmeh Mousavikivaj,Maria Braoudaki,Senthilkumar Kailasam,Yasser Riazalhosseini,Michelle A Sahai,Fotios Drenos,Cristina Sisu,Emmanouil Karteris

Brain research bulletin 173:14-21 PubMed33892085

2021

Depletion of CIP2A inhibits the proliferation, migration, invasion and epithelial-mesenchymal transition of glioma cells.

Applications

Unspecified application

Species

Unspecified reactive species

Zhixing Xu,Xi Chen,Ahmed M Hegazy,Shudong Zhang,Xujie Liu,Jintao Tian,Jin Wu,Fengcai Shi,Lihua Li,Xiaoqun Niu,Jun Pu

Molecular diagnosis & therapy 23:407-417 PubMed30868407

2019

Overexpression of S100A4 Predicts Migration, Invasion, and Poor Prognosis of Hypopharyngeal Squamous Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jianing Xu,Neil Gross,Yuanwei Zang,Shengda Cao,Feilong Yang,Zheng Yang,Wenbin Yu,Dapeng Lei,Xinliang Pan

EBioMedicine 40:263-275 PubMed30651219

2019

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Yu Liu,Tzu-Ting Huang,Yi-Ting Chen,Ji-Lin Chen,Pei-Yi Chu,Chun-Teng Huang,Wan-Lun Wang,Ka-Yi Lau,Ming-Shen Dai,Chung-Wai Shiau,Ling-Ming Tseng

Journal of clinical medicine 7: PubMed30154367

2018

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Yu-Hsiang Huang,Pei-Yi Chu,Ji-Lin Chen,Chun-Teng Huang,Chia-Han Lee,Ka-Yi Lau,Wan-Lun Wang,Yu-Ling Wang,Pei-Ju Lien,Ling-Ming Tseng,Chun-Yu Liu

OncoTargets and therapy 10:5907-5914 PubMed29276394

2017

High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.

Applications

Unspecified application

Species

Unspecified reactive species

Geqi Cha,Jianyu Xu,Xiangying Xu,Bin Li,Shan Lu,Abiyasi Nanding,Songliu Hu,Shilong Liu

British journal of haematology 177:726-740 PubMed28340282

2017

Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Yu Liu,Feng-Shu Hsieh,Pei-Yi Chu,Wen-Chun Tsai,Chun-Teng Huang,Yuan-Bin Yu,Tzu-Ting Huang,Po-Shen Ko,Man-Hsin Hung,Wan-Lun Wang,Chung-Wai Shiau,Kuen-Feng Chen

Breast cancer research : BCR 16:431 PubMed25228280

2014

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Applications

IHC-P

Species

Unspecified reactive species

Chun-Yu Liu,Man-Hsin Hung,Duen-Shian Wang,Pei-Yi Chu,Jung-Chen Su,Tsung-Han Teng,Chun-Teng Huang,Ting-Ting Chao,Cheng-Yi Wang,Chung-Wai Shiau,Ling-Ming Tseng,Kuen-Feng Chen

Cell death & disease 5:e1359 PubMed25077545

2014

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

Applications

IHC-P

Species

Unspecified reactive species

H-C Yu,M-H Hung,Y-L Chen,P-Y Chu,C-Y Wang,T-T Chao,C-Y Liu,C-W Shiau,K-F Chen

Breast cancer research : BCR 14:R68 PubMed22537901

2012

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Applications

IHC-P

Species

Human

Ling-Ming Tseng,Chun-Yu Liu,Kung-Chi Chang,Pei-Yi Chu,Chung-Wai Shiau,Kuen-Feng Chen

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-CIP2A antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CIP2A antibody (AB84547)

Key facts

Host species

Clonality

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Product protocols

Target data

Publications (11)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise